Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Feb;69(2):358-359.
doi: 10.4103/ijo.IJO_40_21.

Commentary: Anti-vascular endothelial growth factor therapies in vitreo-retina practice: Biosimilars versus biologics

Giridhar Anantharaman  1
Affiliations
Comment

Commentary: Anti-vascular endothelial growth factor therapies in vitreo-retina practice: Biosimilars versus biologics

Giridhar Anantharaman. Indian J Ophthalmol. 2021 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None

Comment on

References

    1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31. - PubMed
    1. Gragoudas ES, Adamis AP, Cunnigham ET, Jr, Freinsod M, Guyer DR. Pegatanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–16. - PubMed
    1. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week r.esults of the VIEW studies? Ophthalmology. 2014;121:193–201. - PubMed
    1. Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Understanding biosimilars and its regulatory aspects across the globe: An ophthalmology perspective. Br J Ophthalmol. 2020;104:2–7. - PubMed
    1. Sharma S, Khan M, Chaturvedi A RE-ENACT 2 Study Investigators Group. A multicenter, retrospective study (RE-ENACT 2) on the use of Razumab (world's first biosimilar Ranibizumab) in wet age-related macular degeneration. Ophthalmol Ther. 2020;9:103–14. - PMC - PubMed